Bergen, Norway – 7 April 2022- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, announces that the Board of Directors today approved the 2021 Annual Financial Statements prepared in accordance with International Financial Reporting Standards (IFRS). The Annual Report for 2021 and ESEF file are … Read more
Bergen, Norway, 18 August 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need indications, announces its results for the second quarter and first half of 2020. A presentation and live webcast by BerGenBio’s senior management will take place at 10.00 am CET today, please see below … Read more
Bergen, Norway, 24 February 2020 – Reference is made to the notice on 21 February 2020 and the Board of Directors approval of the Annual Financial Statement. The Annual Report for 2019 is available on the Company’s web site: https://www.bergenbio.com/investors/reports/ -End- For further information, please contact: Richard Godfrey CEO, BerGenBio ASA +47 917 86 … Read more
FDA granted Fast Track Designation for 2L Acute Myeloid Leukaemia (AML) High Impact oral presentation of 2L NSCLC clinical data at SITC Met primary and secondary endpoints in non-small cell lung cancer (NSCLC) Phase II clinical trial in patients previously treated with chemotherapy (cohort A) Proprietary composite AXL tumor immune score (cAXL) identified patients that … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Acute Myeloid Leukaemia (AML): Preliminary Phase II clinical shows promising efficacy for bemcentinib in combo with low-intensity chemo in elderly AML patients unfit for intensive therapy Non small cell lung cancer (NSCLC): Phase II clinical data continues to show promising clinical activity and improved overall survival, particularly in patients with AXL positive tumours including those … Read more
Advanced leukaemia (AML/MDS): Phase II trial fully recruited and combination trial with low-intensity chemotherapy meets efficacy endpoint in hard to treat relapsed / refractory (R/R) leukaemia Advanced lung cancer (NSCLC): Additional cohort added in trial of bemcentinib in combination with anti-PD-1 therapy KEYTRUDA® Anti-AXL antibody, BGB149, commenced phase I safety and pharmacokinetic clinical trial. Bergen, … Read more
Bergen, Norway, 20 February 2019 – The Board of Directors of BerGenBio ASA (OSE:BGBIO) has today approved the Company’s Annual Report for 2018 including the complete 2018 Annual Accounts with notes. The report is attached and available for download at www.bergenbio.com in the section: Investors/Financial Reports. -End- About BerGenBio ASA BerGenBio is a clinical-stage biopharmaceutical company focused on … Read more
Important progress made in 2018: PoC for bemcentinib reported in multiple cancer indications AML/MDS and NSCLC confirmed as target indications for forward development towards registration, starting in 2019 Increasing confidence in bemcentinib safety profile with more than 250 patients dosed Bergen, Norway, 12 February 2019 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for multiple … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.